THE EXPERIENCE OF THE USAGE OF BLOCKER OF AT1-ANGIOTENZINE RECEPTOR APROVEL ON HYPERTENSIVE PATIENTS

Автор(и)

  • G.V. Dzyak
  • T.V. Kolesnik

Ключові слова:

hypertension, AT1-angiotenzine receptor blocker, aprovel, blood pressure monitoring

Анотація

The aim of  the research was to study clinical effects and acceptability of a new AT1-recepotor blocker – irbesartan (aprovel, Sanofi/BMS). 30 patients with soft and moderate arterial hypertension were examined, the average age of the examined persons is 52,6±6,1 years old, duration of disease - 9,7 years. The prescribed dose of aprovel was 150 mg per day for 12 weeks, the dose was corrected after 4 weeks of therapy. All the patients passed 24 hours’ blood pressure monitoring ( device of MEDITEX, ABPM, Hungary) before the start of treatment and on 4, 8, 12after it. The following indices were analyzed: middle systolic and diastolic blood pressure (24-hours, day, night), variability of blood pressure, hypertension time and square indices.  

This study showed the efficacy of aprovel monotherapy (the dose made up 150 – 300 mg per day). The preparation causes a stable hypotensive effect, decreasing systolic and diastolic blood pressure after 6 – 8 week of treatment. The hypotensive effect of aprovel depends on the dose of the preparation. Aprovel does not influence normal circadian low daily blood pressure rhythm and corrects pathologicone. 

Завантаження

Номер

Розділ

Clinical Research

Як цитувати